Table 4.
Induction treatment regimes
| Regime | N (%) |
|---|---|
| Daunorubicine and Cytarabine (n = 116) or Daunorubicine, cytarabine and mitoxantrone (n = 2) |
118 (62.4) |
| Idarubicine and Cytarabine (n = 26) or Idarubicine, Cytarabine and Etoposide (n = 3) |
29 (15.3) |
| Idarubicine, Cytarabine and Cladribine |
20 (10.6) |
| Mitoxantrone, cytarabine and Etoposide (n = 7) or Mitoxantrone and Cytarabine (n = 2) |
9 (4.8) |
| Daunorubicine, Cytarabine and 6-Thioguanine |
8 (4.2) |
| Other/unknown1 | 5 (2.6) |
1Including 2 in clinical trial of combination therapy with Tipifarnib, and 1 with Fludarabine, Cytarabine and G-CSF. 2 patients with unknown treatment but known curative intent.